Tsveta Milanova Sells 2,804 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $35.90 on Thursday. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 3.16 and a beta of 0.87. The stock has a fifty day moving average price of $46.94 and a two-hundred day moving average price of $45.56. Agios Pharmaceuticals, Inc. has a 52-week low of $20.96 and a 52-week high of $62.58.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC increased its holdings in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.